AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure

  • AcelRx Pharmaceuticals Inc ACRX has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management.
  • The study will evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.
  • Endpoints include overall perioperative opioid use, length of post-anesthesia care unit recovery time, outpatient prescription opioid use over the first 24 hours after discharge home, and adverse events.
  • Data will be compared to the historical matched control patients on buprenorphine treated with standard IV opioids in the perioperative setting.
  • Dsuvia, known as Dzuveo in Europe, is indicated for use in adults to manage acute pain severe enough to require an opioid analgesic for which alternative treatments are inadequate.
  • Price Action: ACRX shares are up 0.25% at $1.51 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAGeneralBriefsbuprenorphineOpioids
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!